Matthew Krebs, MBChB, PhD | Authors


The Rationale for Bemcentinib Plus Pembrolizumab in AXL-Positive NSCLC

February 11, 2020

Matthew Krebs, MBChB, PhD, explains the rationale for a phase II study of bemcentinib, a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced non–small cell lung cancer, which he presented at the 2019 Society for Immunotherapy of Cancer Annual Meeting.